19940805

Source:http://linkedlifedata.com/resource/pubmed/id/19940805

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0010181, umls-concept:C0087111, umls-concept:C0242383, umls-concept:C0936012
pubmed:issue	2
pubmed:dateCreated	2010-2-9
pubmed:abstractText	The purpose of this study was to evaluate the cost effectiveness of pegaptanib sodium and ranibizumab injections compared with photodynamic therapy (PDT) with verteporfin for the treatment of choroidal neovascularization secondary to age-related macular degeneration.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309919
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Aptamers, Nucleotide, http://linkedlifedata.com/resource/pubmed/chemical/Photosensitizing Agents, http://linkedlifedata.com/resource/pubmed/chemical/Porphyrins, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/pegaptanib, http://linkedlifedata.com/resource/pubmed/chemical/ranibizumab, http://linkedlifedata.com/resource/pubmed/chemical/verteporfin
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1539-2864
pubmed:author	pubmed-author:BassEric BEB, pubmed-author:BresslerNeil MNM, pubmed-author:CassardSandra DSD, pubmed-author:GowerEmily WEW, pubmed-author:ScheinOliver DOD
pubmed:issnType	Electronic
pubmed:volume	30
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	212-21
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:19940805-Angiogenesis Inhibitors, pubmed-meshheading:19940805-Antibodies, Monoclonal, pubmed-meshheading:19940805-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19940805-Aptamers, Nucleotide, pubmed-meshheading:19940805-Choroidal Neovascularization, pubmed-meshheading:19940805-Cost-Benefit Analysis, pubmed-meshheading:19940805-Drug Costs, pubmed-meshheading:19940805-Health Care Costs, pubmed-meshheading:19940805-Humans, pubmed-meshheading:19940805-Injections, pubmed-meshheading:19940805-Macular Degeneration, pubmed-meshheading:19940805-Models, Economic, pubmed-meshheading:19940805-Photochemotherapy, pubmed-meshheading:19940805-Photosensitizing Agents, pubmed-meshheading:19940805-Porphyrins, pubmed-meshheading:19940805-Quality of Life, pubmed-meshheading:19940805-Quality-Adjusted Life Years, pubmed-meshheading:19940805-Treatment Outcome, pubmed-meshheading:19940805-Vascular Endothelial Growth Factor A, pubmed-meshheading:19940805-Visual Acuity, pubmed-meshheading:19940805-Vitreous Body
pubmed:year	2010
pubmed:articleTitle	A cost-effectiveness analysis of three treatments for age-related macular degeneration.
pubmed:affiliation	Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. egower1@jhmi.edu
pubmed:publicationType	Journal Article, Comparative Study, Research Support, Non-U.S. Gov't